NCT00631631View on ClinicalTrials.gov

Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma

CompletedOBSERVATIONAL
Enrollment

205

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Osteosarcoma
Interventions
DRUG

Mifamurtide (L-MTP-PE)

Solution for intravenous infusion

Trial Locations (2)

10065

Memorial Sloan-Kettering Cancer Center, New York

77030

U.T.M.D. Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT00631631 - Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma | Biotech Hunter | Biotech Hunter